⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALMS News
Alumis Inc. Common Stock
Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus
globenewswire.com
ALMS
CYCN
BFRG
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
globenewswire.com
ALMS
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
globenewswire.com
ALMS
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
globenewswire.com
ALMS
Alumis to Participate in Upcoming November Investor Conferences
globenewswire.com
ALMS